Cargando…
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Our previous experimental studies have shown that the best approach to increase the biological anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association with immunomodulating neurohormones, in an attempt to reproduce the physiological links betwee...
Autores principales: | Lissoni, P., Barni, S., Tancini, G., Ardizzoia, A., Ricci, G., Aldeghi, R., Brivio, F., Tisi, E., Rovelli, F., Rescaldani, R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968792/ https://www.ncbi.nlm.nih.gov/pubmed/8286206 |
Ejemplares similares
-
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
por: Lissoni, P., et al.
Publicado: (1993) -
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
por: Lissoni, P., et al.
Publicado: (1992) -
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
por: Lissoni, P., et al.
Publicado: (1989) -
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
por: Lissoni, P., et al.
Publicado: (1991) -
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
por: Lissoni, P., et al.
Publicado: (1996)